Amgen’s Aranesp Faces More Labeling Changes As A Result Of Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory panel meeting also slated for Q1 2008 as part of pharmacovigilance review of ESAs.